Effect Of Rilapladib (SB-659032) On Platelet Aggregation

A Double Blind, Placebo Controlled, Parallel Study to Evaluate Effects of Repeat Doses of Rilapladib on Platelet Aggregation in Healthy Male Volunteers

The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.

Inclusion Criteria:

• Subjects with QTc < 450 msec as measured at screening.

Exclusion Criteria:

• History of asthma.
• Smokers.